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Graphical abstract of this thesis
Figure 1. Graphical abstract of this thesis. The development of clinically evident EAE involves both pathogenic 
mechanisms in the periphery and inside CNS. In the peripheral compartment, auto-reactive T cells are 
activated with injected antigens presented by APCs in lymphoid organs, such as the lymphocryptovirus 
infected B cell.  During this process, T cells receive 3 signals: I. antigen presentation, II. co-stimulation and III. 
signaling from cytokines (i.e. IL-7) that direct the fate of the T cell response. In marmoset EAE, the activated 
auto-reactive T cells cross the BBB and enter the CNS. In this model, injury to the WM and GM of the CNS is 
variable, and involves activation of resident myeloid cells (microglia) and infiltrated myeloid cells 
(macrophages), which exert cytopathic effects via the production of reactive oxygen species (ROS) and 
cytokines. Oxidative injury caused by ROS contributes to axonal degeneration, and has deleterious 

































MS is a chronic demyelinating disorder of the CNS that is debilitating for patients and 
represents a major health concern for western societies 1-3. Key elements driving 
neurodegeneration and CNS injury include inflammatory demyelination, microglia activation, 
oxidative stress and neuronal mitochondrial defects 4-8. The animal model for MS, i.e. EAE, has 
contributed to the understanding of autoimmune mechanisms operating in the disease and the 
development of therapeutics 9. While rodent EAE is an appropriate model to answer mechanistic 
research questions in some situations, the predictive value of rodent models in relation to 
therapeutic intervention for disease seems to be limited 10. Primate models offer a unique 
opportunity to translate principles discovered in lower species (rodents) to a situation that with 
respect to pathological presentation more closely resembles the human disease 11. The marmoset 
EAE model, in particular, replicates many key features of MS and is therefore an attractive model 
for translational research into pathogenic mechanisms for the human disease 12. 
Leading up to the start of this thesis, several observations and controversies shaped the 
research direction taken. These include: 
• The emergence of a possible role of the IL-7/IL-7R pathway in MS, and a controversy as 
to whether IL-7 contributes to the development of Th1 or Th17 responses 13-16.
• A lack of clarity on if or how EBV could contribute to the development of autoimmunity 
and noteably MS 17-19.
• A new understanding of the importance of cortical pathology in MS 20-24.
• The recognition that the oxidative stress pathway is only partly reflected in rodent EAE, 
yet is a key component of MS 5,6,25,26.
• Growing evidence that mitochondrial defects play a key role in MS disease progression 
8,27,28. 
Therefore, the aims of this thesis were i) to utilize the marmoset EAE model for gaining a 
better understanding of pathogenic mechanisms involved in MS and ii) to characterize NHP 
models to determine how closely they replicate key pathological features of MS. Understanding 
how similar, or dissimilar, a model is with respect to key features of MS is paramount in the model 
selection process for basic (i.e. exploratory research) and applied (i.e. therapeutic testing) 
research (Figure 2).  
While a tremendous amount of work had been done over the last 20 years on refining the 
marmoset EAE model with respect to the adjuvant and encephalitic antigens, refinement of the 
marmoset EAE model had largely taken place prior to the emergence of the importance of GM 
pathology 29,30. At the start of the current project (this thesis), a comparison between immunization 
methods with regard to the ability to elicit WM and GM demyelination had yet to occur. 
Furthermore, key pathological features such as iron accumulation in the NHP brain, or the ability 
of the NHP EAE models to elicit the oxidative stress pathway and mitochondrial alterations had 
also not yet been investigated. The key findings of this thesis are summarized in Box 1. These 
findings, and their contribution to the field, will be discussed in the subsequent sections of this 
chapter. 
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Box 1. Key findings of this thesis.
• Blockade of CD127 delays EAE in fast progressor marmosets, but exerts no detectable 
effect in slow progressor cases.
• The communication process between the LCV-infected B cell and T cell is aberrant 
compared to non-infected B cells; key markers of activation, Th17 responses and 
homing are altered.
• Iron accumulates in myelin and oligodendrocytes in the marmoset and rhesus monkey 
brain.
• Both marmoset and rhesus EAE exhibit MS-like oxidative stress and injury in the brain.  
• The extent of mitochondrial injuries observed in MS is incompletely replicated in EAE. 
• The extent of GM injury in marmoset EAE is highly variable, yet increased in monkeys 









Figure 2. Research strategy.  The non-human primate is used for both exploratory and applied research, which 
are connected in an iterative process. Scientific concepts developed in the exploratory arm are validated in 
the applied arm with therapies that work or do not work in the clinic. For therapies that failed to reproduce 
promising effects obtained in the animal model (forward translation), the reason of failure is examined by 
retesting the treatment in the relevant animal model (reverse translation). This iterative approach led to the 
discovery that lymphocryptovirus-infected B cells have a central pathogenic role in disease progression. 
Understanding how well a model replicates key features of human disease is fundamental in determining the 





Therapeutically targeting the IL-7/IL-7R pathway
The IL-7/IL-7R pathway has been the focus of research attention in MS for several reasons. 
Polymorphisms of the IL7Rα gene are among the more prominent non-HLA- genetic factors to 
confer risk for MS development 16. T cells derived from MS patients exhibit enhanced IL-7R 
expression and IL-7 level is significantly elevated in the CSF of patients 14,16. Constitutive secretion 
of IL-7 by EBV-infected B lymphoblastoid cell lines has also been demonstrated 31. Therefore, in 
chapter 2.1 we assessed the role of the IL-7/IL-7R pathway in the most refined version of the 
marmoset EAE model, namely elicited with MOG34-56/IFA.
One surprising finding in chapter 2.1 was the relatively limited impact of IL-7R (CD127) 
blockade on T-cell subset distribution and responses. Treatment therapeutically or prophylactically 
with anti-IL-7Rα mAb has been shown to mitigate EAE severity in a mouse model induced with 
MOG/CFA by depleting both naïve and effector memory CD4 and CD8 T-cell subsets and altering 
Th1 responses; something not observed in our study 15,32,33. Despite reports on a (in vitro) role of 
IL-7 in expansion of MBP-specific T cells in MS patients, in vivo treatment with the anti- IL-7Rα 
mAb had no detectable effect on ex-vivo MOG34-56-stimulated marmoset T cells 13.
At the start of the thesis research there was considerable controversy regarding the 
contribution of IL-7 to the development of Th1 or Th17 responses 15,34. An early report, which is 
now retracted, demonstrated a role of IL-7 in the survival and expansion of mouse Th17 subset 
34. Others failed to replicate these findings, yet demonstrated a role of IL-7 in the development of 
pathogenic Th1 cells as both murine and human naïve T cells differentiated into Th1 cells when 
stimulated with IL-7 15. Blockade of IL-7R in murine EAE also mitigated disease severity at the 
expense of Th1 responses 15,32. In our study, IL-7R blockade had negligible impact on either IFNγ 
or IL-17A production, regardless of EAE progression, further suggesting that IL-7 has minimal 
impact on the development and expansion of Th1 or Th17 responses. 
We observed that therapeutic intervention in the IL-7/IL-7R pathway with an anti-CD127 
antibody was only successful in a subgroup of monkeys whose placebo-treated twin sibling 
developed EAE in a rapid manner; a phenomenon associated with alterations in the CD20+CD40+ 
B-cell subpopulation. Although these results did not replicate the homogenous response rates 
observed in mouse EAE, our data would predict heterogeneous responses for the human 
population. One final caveat to this data is that IL-7 promotes cytotoxicity of the CD8+ T cell in the 
MS patient, something not seen in rodent models or healthy cohorts; hence the MS T cell may be 
unique with respect to the IL-7/IL-7R signaling pathway 13,14. Thus, although the CD8 cytotoxic T 
cell appears to play a role in the marmoset EAE model, one might expect responses in the MS 
population to be higher than we observed. 
EBV in autoimmunity
Delineating a mechanistic role for EBV infection with the development of autoimmunity and 
MS has been difficult 18. Early reports identifying EBV in the brain of MS patients were met with 
great enthusiasm, yet could not be replicated by other groups and remain controversial 19,35,36. 
Despite this, strong correlation between infectious mononucleosis (IM) and MS, and viral-specific 
Ab titers with relapses suggest an association of EBV with disease development. Hence, a role for 
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EBV in MS warrants further investigation 37. A focus of this thesis was to utilize the marmoset EAE 
model to explore this possible association mechanistically. Prior to the start of the research for 
this thesis it was demonstrated that the marmoset EBV equivalent, CalHV3, played a role in EAE 
progression via altering the secondary lymphoid organ milieu 38,39. In chapter 2.2, we therefore 
examined how EBV infection influences communication between B cells and T cells from MOG34-
56/IFA-immunized marmosets. These results demonstrated that infection with EBV alters key 
receptors and molecules of the B cell that are involved in antigen presentation and co-stimulation 
of the T cell. We demonstrated that the communication process is aberrant between the LCV-
infected B cell and T cell compared to non-infected B cells; phenotypically altering expression of 
critical T-cell markers related to homing, Th17 responses, development and function. 
 The absence of EBV+ B-cells in target-specific tissue, albeit still controversial, added to the 
temporal association of EBV with disease activity would suggest that the EBV-disease association 
either results from dysregulated immune responses to EBV related to disease activity (i.e. IL-10 
secretion) or that infection plays a role in disease progression via immunomodulatory effects in 
the periphery or directly in the CNS in the earliest phase of disease. Recently, Pender and 
colleagues demonstrated that in MS, CD8+ T cells are defective in their ability to control EBV 
infection, which they attributed to an exhaustion of the EBV-specific CD8+ T cell repertoire 40. An 
intriguing single case study showed that revitalization of the repertoire via vaccination against 
EBV induced disease remission in a secondary progressive MS patient 41. Although a direct role in 
the CNS in the earliest phase of the disease cannot be entirely excluded, EBV has never been 
assessed in the CIS brain. The data presented in chapter 2.2 indicate that key pathways involved 
in autoimmunity are dysregulated in the cross talk-between LCV-infected B cells and T cells. 
Concomitantly to our data, collegues from our research group demonstrated the ability of the 
LCV-infected B cell in cross-presenting auto-antigen that would be degraded in non-infected B 
cells 42,43. As demonstrated in the marmoset EAE model, B cell depletion altered the milieu within 
the secondary lymphoid tissues; T cells in B cell depleted SLO maintained high CCR7 expression 
and were retained in the lymph nodes. We could show that co-culture with B-LCL altered 
expression of the homing marker CCR7 in T cells from monkeys that developed clinically evident 
EAE. As will be discussed in the open question section, it remains unanswered if EBV is a causative 
or mere correlative factor for MS 18. The results in this thesis, along with evidence from others, 
would indicate that if EBV is a causative factor of MS, a possible role in disease progression might 




Into the CNS 
The oxidative injury pathway
From a pathogenic point of view, both MS and EAE disease activity can be viewed as 
compartmentalized in peripheral and target tissue compartments 44. For EAE pathogenesis, 
autoreactive T cells are induced by peripheral immunization with myelin antigen resulting in 
tissue injury of the CNS 44. While no unique antigen has been identified in MS, there is an apparent 
nexus between the immune system and damage that occurs in the CNS 45. The fundamental basis 
that EAE models are judged by is their ability to replicate key pathological features observed in 
the MS brain. It is increasingly clear that a model that reflects key aspects of the oxidative injury 
pathway will be vital for development of therapeutics. However, this feature is only partially 
reflected in current rodent EAE models 25.
In chapters 3.1 and 3.3 we assessed aspects of the oxidative tissue injury pathway in primate 
EAE models, with a focus on marmoset EAE, as this model most closely reproduces MS pathology. 
We demonstrated that iron accumulation in myelin and oligodendrocytes in the NAWM and 
NAGM occurs in both the rhesus monkey and marmoset brain at the earliest ages of monkeys 
used for EAE experiments, i.e. 4 and 1.5 years respectively. This represents a clear divergence 
from rodent species used for EAE modeling (rats, mice) and may explain the presence of oxidative 
stress and injury to the CNS observed in the primate models 25.
The MS brain is characterized by the presence of respiratory deficient cells that have lost 
functionality of complex IV (COX-1) due to deletions of mtDNA and/or point base mutations 
leading to loss of individual subunit proteins 27. Furthermore, mitochondrial axonal content is 
increased in the active lesion and differs based upon lesion, myelination and phosphorylation 
status 46,47. The inability of the marmoset model to induce deletions of mitochondrial DNA or 
respiratory deficiency, yet induce loss of individual subunits in the mitochondrial respiratory 
chain (Figure 3), indicates that severe mitochondrial injury may require a degree of chronicity 
that is not likely to be feasible in animal models. The level of oxidative stress exceeds endogenous 
anti-oxidant capabilities in the MS patient. Testing therapeutics directed at this pathway in 
models where oxidative stress does not exceed endogenous anti-oxidant activity likely has 
minimal predictive value for clinical efficacy, underscoring the value of NHP models in this area of 
research. 
Cortical pathology
The importance of cortical pathology in the MS brain with respect to disease progression and 
clinical symptoms is becoming increasingly clear 23. This critical feature of disease pathology is 
frequently absent in mouse EAE models, yet distinctly present in strains of Lewis rats and in 
marmoset EAE models 49. In chapter 3.2 we performed a comparative analysis of the ability to 
elicit GM pathology with the different EAE induction methods in marmosets. We demonstrated 
that previous estimates of cortical pathology development were much lower than actually 
observed numbers. This is likely due to reliance on MRI diagnosis. We observed that the amount 
of demyelination varied between immunization protocols. Although the use of IFA in EAE 
induction is more animal welfare friendly, it clearly elicited less cortical demyelination than was 
observed in EAE models based on CFA. Interestingly, all marmoset EAE models exhibited the 
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same predilection sites with respect to development of subpial demyelination. Like MS, low flow 
areas such as deep sulci were frequently affected 22,50,51. Furthermore, in marmosets immunized 
with MOG34-56 emulsified in either CFA or IFA, antibodies directed against conformational MOG 
were not observed, unlike in rhMOG-immunized animals, confirming previous results 30. Whereas 
histologically we could observe signs of IgG and complement deposition in the early active 
lesions in the WM or in leukocortical lesions, identification of early active cortical lesions by MOG 
staining is challenging and clear uptake of IgG and C9neo by macrophages in WM and leukocortical 
lesions was not easily discernable. It is unclear if this staining pattern represents pathogenic 
antibodies binding other myelin antigens or if this is a non-specific pattern as described by 
Prineas and colleagues 52. Future studies are warranted to eliminate the possibility of a pathogenic 
antibody directed against myelin constituents other than MOG. 
Outstanding questions
Is EBV a causative or correlative factor of MS? 
One of the most challenging questions that remains to be answered is if EBV is a causative 
factor for MS, and thus actively contributing to disease progression, or if the correlation is a non-
relevant bystander effect (guilt-by-association) 18. Proposed roles of EBV in disease progression, 
including those in this thesis, remain largely speculative and are based on ex vivo and in vitro cell 
cultures. 
A causative role of EBV for disease initiation or progression would considerably change 
therapeutic strategies in early stages of disease as immune modulation could be directed against 
virus-infected cells 53. Therapies that compromise the immune system, and have negative side 
effects, would not be necessary; patients that develop IM could be prophylactically treated, 
thereby avoiding the development of MS. Yet, significant challenges exist. Once latency is 
established, anti-viral therapies are ineffective in EBV-related lymphoproliferative disorders and 
therefore might also not be successful in MS 54. Depletion of CD20+ B cells would eliminate the 
Figure 3. Mitochondrial alterations in marmoset EAE. The axonal mitochondrial (mt) content was assessed in 
relation to the phosphorylation status of neurofilament, as a marker of inflammation-related pathology 48. A-B 
shows staining of normally phosphorylated (blue; SMI31+) or EAE-related non-phosphorylated (blue; SMI32+) 
neurofilament with cytochrome C oxidase subunit 1 (red; COX-1) and porin, a voltage dependent anion 
channel (VDAC) expressed in the outer membrane of all mitochondria (green). Shown in C-D is that while the 
number of mitochondria did not differ between SMI31+ and SMI32+ axons (injured), the percentage of axonal 
area occupied by mitochondria was significantly increased in SMI32+ axons. To determine the activity of 
mitochondria (E-G), we examined the dynamics between COX-1, a mtDNA encoded member of the COX 
catalytic core, and porin. In relation to SMI31+ axons, SMI32+ axons exhibited significantly lower levels of 
inactive (= COX-1 negative) mitochondria (absolute deficiency; E), and significantly higher levels of active (= 
COX-1 positive) mitochondria (F). The percentage of mitochondria deficient axons or mitochondria lacking 
COX-1 immunoreactivity, was significantly lower in SMI32+ axons in comparison to SMI31+ axons (G). Using 
COX histochemistry combined with fluorescent labeling, we observed a partial loss of COX activity in astrocytes 
and neurons (H-M), but not in macrophages (data not shown). Cells that had partial activity loss were 
observed in EAE lesions, absent in healthy controls, and frequently exhibited a loss of individual complex IV 
subunits COX-1 (L-M). Non-lesion associated loss of COX-1 was observed in purkinje cells (data not shown). 
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reservoir for EBV, yet a specific role for EBV and MS cannot be conferred from this treatment as 
large populations of B cells and minor populations of T cells are eliminated 53. Furthermore, mAb 
may have difficulties passing the BBB depending on the integrity of the barrier; thus to entirely 
eliminate the EBV+ B cell pool the therapeutic must be delivered intrathecally 55. Recently a case 
report was published showing that adoptive immunotherapy whereby autologous EBV-specific 
CD8+ T cells were expanded in vitro and transferred back to a SPMS patient led to the induction 
of remission. Although the patient benefited from the transfer, a larger sample size is needed to 
be able to draw information as to how successful this therapy will be 41. 
The role of iron in EAE and MS: amplification or remyelination? 
Iron is an essential element required for normal brain health as a contributing co-factor for 
mitochondrial respiratory complexes, oligodendrocyte precursor cell proliferation and the (re)
myelination process 56. On the other hand, unbound iron can contribute to oxidative tissue injury 
by the generation of hydroxyl radicals from hydrogen peroxide via the Haber-Weiss reaction. Iron 
metabolism is dysregulated in the MS brain and the destruction of myelin and oligodendrocytes 
is associated with altered expression of iron metabolic markers and perilesional accumulation of 
iron in myelin, oligodendrocytes and microglia 6. Recently, it has been demonstrated that lesions 
forming iron rims are more likely to expand than those not forming iron rims 57. This finding, 
however, is correlative and since iron rim lesions were larger at the start of the observation 
period one cannot deduce if iron itself is attributed to the expansion of the lesion 57. In rodent 
EAE, iron deficiency attenuated symptoms of disease 58. These effects though were associated 
with immune suppression, and importantly iron overloading did not exacerbate EAE 58. 
Unfortunately, clinical trials of iron chelation have been limited in size and number, predominantly 
based on PPMS or SPMS patients and yielded mixed results 59. As shown in chapter 3.1 and 3.3 
NHP EAE models offer attractive systems for preclinical testing of iron chelation therapies. 
Whereas the NHP brain exhibits profound iron accumulation, this is limited in the rodent brain at 
ages used for experimental modeling 25. The marmoset model is particularly well suited for this 
research as twin animals can be used for studies and unlike humans, these monkeys are fed 
standardized diets; the possible effect of dietary iron intake and variation in basal brain deposition 
levels of humans could confound studies using too few patients. 
Is inhibiting oxidative stress a feasible strategy to alter disease activity?
Enhancement of anti-oxidant activity, and cessation of oxidative stress mechanisms has been 
proposed as an attractive therapeutic strategy to delay the conversion from RRMS to SPMS 60-62. 
Recent clinical success of Nrf2 stimulation with dimethyl-fumerate (DMF) indicates that targeting 
the oxidative stress pathway may yield a favorable outcome63. The clinical effect of DMF cannot 
be entirely attributed to stimulation of the Nrf2 pathway, as innate and adaptive immune 
response modulation by DMF has been observed independent of Nrf2 stimulation 64. In MOG-
induced rodent EAE models, targeting the NADPH complex function has a significant impact on 
disease and thus there is clear evidence to support such a strategy 65,66. Alleviating oxidative 
stress and injury could reduce or delay the development of defective mitochondria, spare axons 
from insult and degeneration, and prevent energy diversion from the remyelination process 60. 




would likely target other tissues as well and may increase the patient risk to infection. Hence, the 
ideal effective therapy would be CNS specific 67. As reduction of stress can also have deleterious 
consequences for mitochondria and as ROS also play a key role in angiogenesis, oxygen sensing, 
cell proliferation and signaling, it is vital that this underlying mechanism is well understood; 
potential therapeutics need therefore to be tested in models that reflect human-like levels of 
oxidative stress 68,69. As presented in chapter 3.1 and chapter 3.3, the NHP EAE models are 
attractive models for testing therapeutics and underlying mechanisms involving oxidative stress. 
Can marmoset EAE be modified to induce 100% incidence of GM pathology?
One of the prominent features of marmoset EAE is the ability of monkeys to elicit GM 
pathology 70,71. As presented in chapter 3.2 the incidence of GM pathology varies per immunization 
protocol. In our own unpublished data, we have noticed that some therapeutic interventions, 
regardless of outcome of treatment, result in alterations of GM lesions. For instance, monkeys 
treated with an antibody against the B cell growth and differentiation factor “a proliferation-
inducing ligand” (APRIL) developed GM lesions at a 100% incidence rate, yet the treatment had 
little effect on disease outcome (own unpublished observations). This suggests that the EAE 
induction method can be altered in a way that would favor the development of cortical pathology. 
Cortical demyelination in the Lewis rat can only be observed in the LEW.1AR1 (RT1r2) and 
LEW.1W(RT1u) strains that contain RT1.BuDu MHC-II and RT1.Aa MHC-I alleles 49. In these strains, 
extensive cortical demyelination develops and does so in a reproducible fashion. The MHC allelic 
variation has yet to be assessed for the marmoset in relation to development of cortical 
pathology; however it should be noted that marmoset MHC equivalent (Caja) alleles are fairly 
conserved 72. As oxidative stress in the marmoset model was not confined to the immunization 
method but rather dependent upon demyelinating activity, effort should be placed in refining the 
model to develop higher incidences of cortical pathology. 
Future perspectives
Arguably, few phrases better embodies the state of MS research activities than that attributed 
to French Neo-Platonist philosopher Bernard of Chartes: “Standing on the shoulder of giants”. 
Through success and failures, knowledge of pathogenic mechanisms has been greatly expanded 
and now therapeutic regimens can modify disease course. Yet still, the cause of MS is unknown 
and current therapeutics only variably modify disease; development of effective therapeutics for 
progressive forms of disease is critical and refinement of treatment regimens for RRMS is greatly 
needed 73.
Despite this pressing need for therapeutic refinement and development, optimism is 
warranted. Efforts to develop tissue banks across Europe and the US has granted researchers 
access to tissues that would have previously been difficult to obtain 74. Technological advances 
such as single cell technologies, multiplexing and high throughput technologies allow screening 
not previously possible 75. Animal models will undoubtedly play a role in research efforts. As 
shown in this thesis, the NHP models replicate many key features of disease and will be valuable 
models in these efforts. 
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